Navigation Links
Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation
Date:7/29/2008

enting the interaction of beta amyloid with copper and zinc. MPACs have been shown to restore normal function to beta amyloid-impaired synapses and improve cognitive performance in mouse models of Alzheimer's.

Jeffrey L. Cummings, MD, of the David Geffen School of Medicine at UCLA, Los Angeles, CA, reports on a Phase IIa randomised, double-blind, placebo-controlled trial of PBT2 to assess the safety, tolerability, biochemical impact on the body, and preliminary efficacy of two different doses of the compound in patients with early Alzheimer's. This was done by (1) looking at how treatment with PBT2 changed the levels of proteins that are believed to be linked to Alzheimer's in the blood and spinal fluid (CSF) and (2) using memory and thinking tests to assess any change in the participants' mental capacity.

Seventy-eight (78) people with mild Alzheimer's (mean MMSE=22.9) were randomized to receive placebo (n=29), PBT2 50mg (n=20) or PBT2 250mg (n=29) capsules orally, once per day for 12 weeks. Biomarker assessment included the mean change from baseline to week 12 of proteins AB42 and AB40 in CSF. Preliminary efficacy assessments included the mean change from baseline to week 12 on a Neuropsychological Test Battery (NTB) and the ADAS-cog.

The researchers found that PBT2 250mg demonstrated a statistically significant reduction of CSF AB42 after 12 weeks of treatment compared with placebo (p=0.006), which was dose-dependent (p=0.023). PBT2 250mg demonstrated statistically significant improvements in both the Trail Making Test Part B and the Category Fluency Test (components of the NTB related to executive function) compared with placebo (p=0.009 and p=0.041, respectively). PBT2 had no effect on the ADAS-cog in this trial.

The researchers found the safety and tolerability profile to be similar between PBT2 and placebo. The overall withdrawal rate in the study was 5 percent, with no withdrawals attributed to adverse events. There were no seriou
'/>"/>

SOURCE Alzheimer's Association
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
2. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
4. Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation
5. Controversy About Lack of Placebo Group Decline in Alzheimers Clinical Trials
6. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
7. Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer
8. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
9. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
10. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
11. Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Aug. 28, 2014 /PRNewswire-iReach/ -- Gateway Analytical announced ... 9 th Annual Global Pharma Manufacturing Summit ... 8-9 th . The Global Pharma Manufacturing Summit ... small molecule and biologic pharmaceutical manufacturing. The conference ... today,s manufacturers face, such as the increasing pressure ...
(Date:8/28/2014)... , Aug. 28, 2014  Robotic surgery is ... media, both for the promise of improved outcomes ... quick deployment of surgical robots and market pressures ... facilities to evaluate their robotic surgery training programs ... team.    ECRI Institute ( www.ecri.org ...
(Date:8/28/2014)... THOUSAND OAKS, Calif. , Aug. 28, 2014 /PRNewswire/ ... the submission of a Biologics License Application (BLA) to ... seeking approval for the treatment of high cholesterol. Evolocumab ... proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that ... (LDL-C), or "bad" cholesterol, from the blood. 1 ...
Breaking Medicine Technology:Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9
... Mass. , July 26 The Exergen ... nationwide that stock the Exergen TemporalScanner™, according to data ... of all types of thermometers, including national brands and ... found Exergen came out on top. Exergen,s retail unit ...
... , NEWARK, Del. and GRONINGEN, Netherlands ... a leading full-service GLP/GCP-compliant contract research organization providing testing ... announced the completion of its acquisition of Xendo Drug ... .  XDD, a European contract research organization (CRO), will ...
Cached Medicine Technology:Exergen TemporalScanner Thermometer Best Selling Brand at Retailers 2QPS Announces the Acquisition of Xendo Drug Development 2QPS Announces the Acquisition of Xendo Drug Development 3QPS Announces the Acquisition of Xendo Drug Development 4
(Date:8/28/2014)... 2014 Millennium Treatment Group is ... This month will be a celebration of the ... services. Along with other treatment facilities and mental ... spread the word about this national observance. , ... work of treatment and recovery professionals, and has ...
(Date:8/28/2014)... FL (PRWEB) August 28, 2014 Millennium ... use affecting users in the workplace. A recent ... Dependence (NCADD) states that drug abuse is costing ... who use or are addicted to drugs affect their ... activities carry over into the workplace, causing expensive problems ...
(Date:8/28/2014)... HealthDay Reporter THURSDAY, Aug. 28, 2014 ... worsen symptoms of multiple sclerosis (MS), a new study from ... vitamin D, smoking and Epstein Barr virus infection. Our study ... affecting MS patients," said lead researcher Dr. Mauricio Farez, of ... Multiple sclerosis is a disease of the nervous system ...
(Date:8/28/2014)... York, New York (PRWEB) August 28, 2014 ... second federal bellwether trial of a transvaginal mesh ... by Ethicon, Inc., Bernstein Liebhard LLP reports. Court ... District of West Virginia indicate that the case ... had to undergo two revision surgeries, allegedly due ...
(Date:8/28/2014)... August 28, 2014 Allegheny ... today a regional partnership designed to advance sports ... for competitive young athletes, scholastic athletes and their ... Strong Body & Mind Initiative will offer a ... the physical and mental dynamics involved in pursuing ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Celebrates National Recovery Month 2Health News:Drug Use Causes Problems in the Workplace 2Health News:Could Too Much Salt Harm MS Patients? 2Health News:Could Too Much Salt Harm MS Patients? 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 2Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 3Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 4
... N.C., Nov. 2 Just how much of the time,that ... due to,administrative tasks and internal communication? Pharmaceutical sales directors ... of the time used for internal communication - or 6 ... in lost sales every year,according to a recent research study ...
... HILL, N.C., Nov. 2 Records and Information,Management ... in the success of,their parent organizations through reducing ... Today the programs account for,over $1.5 million in ... leader,Best Practices, LLC. This number will continue ...
... each point scored, CENTENNIAL, Colo., Nov. 2 ... show support for their favorite team -- camping,out for ... for the big game. Now five football teams are ... of a deadly disease --,prostate cancer. The Denver ...
... Inc.,(Nasdaq: IDMI ) today announced the presentation of ... patients,with lung metastases as a result of the progression ... typically affects children and young,adults. The data show that ... exhibited signs of disease control. "These results are ...
... Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) today announced ... for review the Company,s New Drug,Application (NDA) for NEBIDO(R), ... hypogonadism. The FDA Prescription,Drug User Fee Act (PDUFA) target ... was submitted to the FDA by the Company on ...
... Corporation,(Nasdaq: MNKD ), focused on discovering, developing and commercializing,treatments ... at,the following conferences: * The Acumen BioFin Rodman & ... November 6, 2007 at 2:20 PM ET at the New ... * The CIBC 18th Annual Healthcare Conference on Wednesday ...
Cached Medicine News:Health News:New Pharmaceutical Sales Force Communication Metrics: Nearly 6 Weeks of Sales Time per Rep Wasted Each Year 2Health News:New Records & Information Management: Are You Spending Right on Records Management, Data Security and Compliance? 2Health News:Professional Football Takes the Field to Tackle Prostate Cancer 2Health News:Professional Football Takes the Field to Tackle Prostate Cancer 3Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 2Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 3Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 4Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 5Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 6Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 7Health News:FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus 2Health News:FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus 3Health News:FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus 4
... Introducing the new PRONEB® ULTRA compressor. ... treatment time while delivering more medication to ... PARI LC PLUS® or PARI LC STAR® ... are optimized for inhalation and retention into ...
... Compressed Air., ,Allied Healthcares Timeter® PCS 414 ... other air compressors that you may wonder if ... PCS 414 features a durable, mar-resistant steel case ... unit weighs only 26.5 pounds. The PCS 414 ...
... DC powered compressor nebulizer system available. ... to take nebulizer treatments away from ... the included AC power adapter or ... The integral reusable jet nebulizer kit ...
The 45 PSI SuperSportNeb provides superior performance that translates to shorter treatment times. Like the SportNeb, it is constructed with die-cast aluminum compressor components for consistent rel...
Medicine Products: